Piper Sandler Reiterates Overweight Rating on Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Piper Sandler analysts reiterated a Overweight rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on February 23, 2026. Bristol-Myers Squibb Company PFD CONV 2 operates…
Read more
